Kintara Therapeutics Inc KTRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KTRA is a good fit for your portfolio.
News
-
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.’s KVA12123 Novel anti-VISTA Checkpoint Inhibitor
-
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor
-
Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones
-
Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones
-
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
-
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
-
Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results
-
Kintara Therapeutics Shares Up 19% After NIH Grant
Trading Information
- Previous Close Price
- $0.22
- Day Range
- $0.21–0.25
- 52-Week Range
- $0.08–5.00
- Bid/Ask
- $0.24 / $0.25
- Market Cap
- $13.54 Mil
- Volume/Avg
- 2.3 Mil / 12.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 2
- Website
- https://www.kintara.com
Valuation
Metric
|
KTRA
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
KTRA
Financial Strength
Metric
|
KTRA
|
---|---|
Quick Ratio | 4.89 |
Current Ratio | 5.04 |
Interest Coverage | — |
Quick Ratio
KTRA
Profitability
Metric
|
KTRA
|
---|---|
Return on Assets (Normalized) | −199.84% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −527.09% |
Return on Assets
KTRA
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Fzqtjhsx | Kyrhn | $565.6 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Dwdzqtj | Chrnnk | $127.8 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Txqtjqjly | Fljxwr | $118.7 Bil | |||
Moderna Inc
MRNA
| Shzblzcx | Zdnwp | $46.8 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Rgpsyvw | Cpjntb | $29.7 Bil | |||
argenx SE ADR
ARGX
| Gjvfzbkw | Ycnf | $29.3 Bil | |||
BioNTech SE ADR
BNTX
| Dtnrsgqc | Xtn | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Bmtyhtkn | Wmpwk | $16.1 Bil | |||
United Therapeutics Corp
UTHR
| Qmzgkfwk | Hfpw | $15.0 Bil | |||
Incyte Corp
INCY
| Vqdpkqyk | Knpmd | $13.5 Bil |